Detailed Narrative
Robust Q4 & FY25 Financial Performance
Yatharth Hospitals reported a strong Q4 FY25 with revenue growing 30% YoY to INR 2,318 million and EBITDA increasing 23% YoY to INR 570 million, achieving a 24.6% EBITDA margin. For the full FY25, revenue surged 31% YoY to INR 8,805 million, and EBITDA grew 22% YoY to INR 2,202 million, with a 25% EBITDA margin. Net profit for FY25 stood at INR 1,306 million, up 14% YoY, while Q4 net profit was INR 387 million, up 1% YoY, primarily due to increased depreciation from ongoing expansion.
Strategic Expansion and Capacity Additions
The company made significant strides in expansion, with the Greater Faridabad facility (200 beds) contributing INR 436 million in revenue (9% of Q4 total) within 10 months of operation. Two new hospitals, one 400-bed facility in Faridabad and a 300-bed facility in New Delhi, are expected to be fully operational by the start of Q2 FY26. These new facilities are projected to reach EBITDA breakeven within 12-15 months of operationalization, starting with an ARPOB closer to INR 35,000 and an occupancy of 30-35%.
Improving ARPOB and Payer Mix
Group ARPOB increased by 7% YoY to INR 31,441 in Q4 FY25. Noida Extension reported the highest ARPOB at INR 38,806, an 11% YoY increase, driven by 70% contribution from super-specialty services. Management aims to improve the revenue mix by focusing on high-end tertiary and quaternary care in new hospitals, which are expected to have a significantly lower government business mix (around 20% compared to the group average of 37%), thereby enhancing overall ARPOB.
Working Capital and Receivables Management
Despite higher receivable days due to a larger government business mix compared to peers, the company generated a strong operating cash flow of INR 1,496 million in FY25, with a cash conversion ratio of approximately 70%. Management expects receivable days for the overall group to reduce by 20-25 days over the next 2-3 years, with newer facilities initially targeting 60-80 receivable days, as their government business mix will be lower.
Future Capex and Growth Outlook
Yatharth plans a capex of INR 300-310 crores for FY26 and FY27, allocated across its existing 7 hospitals and the new Delhi and Faridabad facilities, primarily for medical equipment and construction. The company also intends to add at least one new facility through inorganic acquisition this financial year, with an estimated capex of INR 80 lakhs to INR 1 crore per bed (excluding land). Management is confident in sustaining a 30% yearly top-line growth momentum for the coming financial years.
Income Tax Matter and Corporate Governance
A significant positive development was reported regarding the income tax matter, with AKS Medical (Noida Extension Hospital, contributing 40% of group revenue) depositing INR 12.38 million as additional tax. Management is confident that the remaining assessment for the parent entity will be resolved soon without material financial impact. BDO India has been proposed as the new statutory auditor from FY26, pending board and AGM approvals, reinforcing commitment to corporate governance.
Focus on North India and Super-Specialty Services
The company's strategy is to solidify its presence in North India, including Delhi NCR, UP, Haryana, Punjab, Rajasthan, and Bihar, rather than expanding into distant geographies. This regional focus leverages existing brand visibility and ease of doctor attraction. New hospitals will emphasize high-end super-specialty services, with oncology, neurosurgery, and cardiac surgery departments growing faster, aiming for 60-70% super-specialty contribution in each hospital.